Page 12 - Creative Commons Attribution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Creative commons attribution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Creative Commons Attribution Today - Breaking & Trending Today

Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study

Objective To investigate whether use of glucagon-like peptide 1 (GLP1) receptor agonists is associated with increased risk of thyroid cancer.

Design Scandinavian cohort study.

Setting Denmark, Norway, and Sweden, 2007-21.

Participants Patients who started GLP1 receptor agonist treatment were compared with patients who started dipeptidyl peptidase 4 (DPP4) inhibitor treatment, and in an additional analysis, patients who started sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment.

Main outcome measures Thyroid cancer identified from nationwide cancer registers. An active-comparator new user study design was used to minimise risks of confounding and time related biases from using real world studies of drug effects. Cox regression was used to estimate hazard ratios, controlling for potential confounders with propensity score weighting.

Results The mean follow-up time was 3.9 years (standard deviation 3.5 years) in the GLP1 receptor agonist group an ....

United States , Karolinska Institutet , Eli Lilly , Drottning Victorias Frimurarestiftelse , Konung Gustaf , Swedish Research Council , European Medicines Agency , Lundbeck Foundation , Drug Administration , Danish Cancer Society , Swedish Cancer Society , Boehringer Ingelheim , Novo Nordisk Foundation , World Health Organization , Research Foundation Denmark , Novo Nordisk , Independent Research Foundation Denmark , Merck Sharp , Open Access , Creative Commons Attribution ,